well yes true they don’t have the money anyway so Ok make the best of what they have now with pancreatic. //but if you look at investor slides from around 2014/15 they have shown some results in old liver cancer trials and results looked quite good so pity like with other things the former board ceo cmo didn’t looked at & invest in more seriously long time ago. //also on that same slide about “alternative delivery”, the other thing they say is expand label with folfirinix chemo. This could be very very important in Europe and may have caused a bigger barrier to uptake of device than we realise. IMO.
OSL Price at posting:
4.6¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)